QN-Palm-POD / siLuc topical eye drop (luciferase knockdown)
Sequence: CGGGARKKAAKAARKKAAKAARKKAAKAARKKAAKA
| Experiment Id | EXP001972 |
|---|---|
| Paper | Effective In Vivo Topical Delivery of siRNA and Gene Silencing in Intact Corneal Epithelium Using a |
| Peptide | QN-Palm-POD / siLuc topical eye drop (luciferase knockdown) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | 140:1 (700 µM QN-Palm-POD + 5 µM siRNA) applied daily for 4 days (split-eye design). |
| Formulation Format | CPP–siRNA polyplex with covalent endosomal disruptor (topical ocular delivery) |
| Formulation Components | QN-Palm-POD complexed with siLuc (right eye) vs NSC4 (left eye); luciferase activity monitored in vivo. |
| Size Nm | 107.00 |
| Zeta Mv | 14.90 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Mouse Krt12+/luc2 corneal epithelium luciferase reporter model (split-eye control: siLuc vs NSC4) |
| Administration Route | Topical eye drop daily for 4 days (2.5 µL per eye); IVIS luciferase imaging |
| Output Type | In vivo functional RNA delivery (reporter gene silencing) |
| Output Value | Up to ~30% knockdown of corneal luciferase signal (max around day 9; significant after treatment withdrawal). |
| Output Units | |
| Output Notes | Histology and clinical eye exams reported no swelling/edema/inflammation in treated eyes. |
| Toxicity Notes | No corneal abnormalities on H&E; eyes remained 'quiet' by ophthalmic exam during and after treatment. |
| Curation Notes |